5247422025-10-012025-12-315247422025-12-315247422025-04-012025-12-315247422025-10-012025-12-31in-capmkt:OtherExpenses1Member5247422025-04-012025-12-31in-capmkt:OtherExpenses1Member5247422025-10-012025-12-31in-capmkt:ReportableSegments1Member5247422025-10-012025-12-31in-capmkt:ReportableSegments2Member5247422025-10-012025-12-31in-capmkt:ReportableSegments3Member5247422025-04-012025-12-31in-capmkt:ReportableSegments1Member5247422025-04-012025-12-31in-capmkt:ReportableSegments2Member5247422025-04-012025-12-31in-capmkt:ReportableSegments3Member5247422025-10-012025-12-31in-capmkt:ReportableSegments1Member5247422025-10-012025-12-31in-capmkt:ReportableSegments2Member5247422025-10-012025-12-31in-capmkt:ReportableSegments3Member5247422025-04-012025-12-31in-capmkt:ReportableSegments1Member5247422025-04-012025-12-31in-capmkt:ReportableSegments2Member5247422025-04-012025-12-31in-capmkt:ReportableSegments3Member5247422025-10-012025-12-31in-capmkt:ReportableSegments1Member5247422025-12-31in-capmkt:ReportableSegments1Member5247422025-10-012025-12-31in-capmkt:ReportableSegments2Member5247422025-12-31in-capmkt:ReportableSegments2Member5247422025-10-012025-12-31in-capmkt:ReportableSegments3Member5247422025-12-31in-capmkt:ReportableSegments3Member5247422025-10-012025-12-31in-capmkt:ReportableSegments1Member5247422025-12-31in-capmkt:ReportableSegments1Member5247422025-10-012025-12-31in-capmkt:ReportableSegments2Member5247422025-12-31in-capmkt:ReportableSegments2Member5247422025-10-012025-12-31in-capmkt:ReportableSegments3Member5247422025-12-31in-capmkt:ReportableSegments3Member5247422025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15247422025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25247422025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15247422025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25247422025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15247422025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524742CAPLIPOINTNOTLISTEDINE475E01026CAPLIN POINT LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-02-052026-01-27INRCroresQuarterlyThird quarterGeographical2026-02-0511:00:002026-02-0513:00:00Not applicable2025-10-012025-12-31UnauditedConsolidated542770000033680000057645000008924000001280000000-21000000497800000180000019280000088160000037254000002039100000020391000003564000002390000038030000001658800000000-20000016586000001684000001827000000163880000019800000180720000019800000152000000221.5621.510021.5621.511. The above Consolidated Financial Results for the quarter and Nine Months ended December 31, 2025, have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on February 5, 2026, and reviewed by the Statutory Auditors. <BR> <BR> 2. The unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA). Accordingly, segment reporting has been presented along with the Consolidated results. <BR> <BR> 4. During the quarter and Nine Months ended December 31, 2025, the Company has allotted NIL equity shares of Rs. 2 each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as of December 31, 2025, and 7,60,11,696 as of December 31, 2024. The Company had allotted NIL shares and 69,950 shares during the quarter ended and Nine Month ended December 31, 2024, respectively. <BR> <BR> 5. Pursuant to the notification of the New Labour Codes effective 21st November, 2025 by Government of India, whereby multiple existing labour legislations have been consolidated into a unified framework, the Group has assessed the implications of the revised definition of “wages” for employees in India. The assessment has resulted in an increase in gratuity and compensated absence related employee benefit obligations aggregating to Rs. 1.39 Crores and the impact of the same has been taken in the current quarter results. <BR> The Company continues to monitor developments pertaining to the New Labour Codes, and the impact thereof, if any, will be accounted for in accordance with applicable accounting standards. <BR> <BR> 6. Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary. <BR> 2025-04-012025-12-31UnauditedConsolidated158703000008718000001674210000025509000003631800000241000001401800000510000053970000026956000001084900000058931000000589310000010527000007230000011250000000476810000000040000047685000006474000005415900000471130000057200000535870000057200000152000000261.9861.80061.9861.8Other Expenses881600000Other Expenses2695600000Rest of the World4329300000USA1098400000Unallocated336800000Rest of the World12635400000USA3234900000Unallocated871800000576450000016742100000576450000016742100000Rest of the World1603000000USA99100000Unallocated336800000Rest of the World4678700000USA343000000Unallocated8718000002038900000589350000020389000005893500000Rest of the World17200700000USA6179100000Unallocated1380580000037185600000037185600000Rest of the World2730500000USA655500000Unallocated0338600000003386000000Remeasurements of Defined Benefit Plan-9500000Income tax relating to these items2400000-7100000Remeasurements of Defined Benefit Plan3900000Income tax relating to these items-1000000290000000Exchange difference in translating the financial statements of foreign operations175500000175500000Exchange difference in translating the financial statements of foreign operations64450000064450000000168400000647400000